MCID: LMN015
MIFTS: 44

Luminal Breast Carcinoma a

Categories: Cancer diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Luminal Breast Carcinoma a

MalaCards integrated aliases for Luminal Breast Carcinoma a:

Name: Luminal Breast Carcinoma a 11 14
Breast Tumor Luminal 11 16
Luminal a Breast Carcinoma 11
Luminal Breast Cancer 11

Classifications:



External Ids:

Disease Ontology 11 DOID:0060548
NCIt 49 C53554
UMLS 71 C3642345

Summaries for Luminal Breast Carcinoma a

Disease Ontology: 11 A breast carcinoma that is characterized by high expression of genes characteristic of luminal epithelial cells, including estrogen receptor (ER), estrogen regulated protein LIV-1, and the transcription factors hepatocyte nuclear factor 3, HNF3A, XBP1, and GATA 3.

MalaCards based summary: Luminal Breast Carcinoma a, also known as breast tumor luminal, is related to estrogen-receptor positive breast cancer and conotruncal heart malformations. An important gene associated with Luminal Breast Carcinoma a is HJURP (Holliday Junction Recognition Protein), and among its related pathways/superpathways are Chromatin Regulation / Acetylation and Chromosome Maintenance. The drugs Palbociclib and Goserelin have been mentioned in the context of this disorder. Affiliated tissues include breast, bone marrow and lymph node, and related phenotypes are Increased Salmonella-containing vacuole maturation and Increased Salmonella enterica Typhimurium binding

Related Diseases for Luminal Breast Carcinoma a

Diseases in the Luminal Breast Carcinoma a family:

Luminal Breast Carcinoma B

Diseases related to Luminal Breast Carcinoma a via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 36)
# Related Disease Score Top Affiliating Genes
1 estrogen-receptor positive breast cancer 10.4
2 conotruncal heart malformations 10.3
3 rhabdomyosarcoma 2 10.1
4 ductal carcinoma in situ 10.1
5 neuroendocrine tumor 10.1
6 breast ductal carcinoma 10.1
7 breast cancer 10.0
8 familial adenomatous polyposis 1 10.0
9 prostate cancer 10.0
10 trichorhinophalangeal syndrome, type i 10.0
11 down syndrome 10.0
12 factor vii deficiency 10.0
13 fanconi anemia, complementation group d2 10.0
14 insulin-like growth factor i 10.0
15 mismatch repair cancer syndrome 1 10.0
16 leukemia, acute myeloid 10.0
17 epidermolysis bullosa simplex superficialis 10.0
18 fanconi anemia, complementation group l 10.0
19 intrauterine growth retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, and genital anomalies 10.0
20 immunodeficiency, common variable, 10 10.0
21 familial adenomatous polyposis 10.0
22 breast lobular carcinoma 10.0
23 lymphoma 10.0
24 rickets 10.0
25 neutropenia 10.0
26 brain cancer 10.0
27 squamous cell carcinoma 10.0
28 gastric antral vascular ectasia 10.0
29 adenocarcinoma 10.0
30 multiple endocrine neoplasia 10.0
31 breast adenocarcinoma 10.0
32 turner syndrome 10.0
33 tubular adenocarcinoma 10.0
34 severe combined immunodeficiency 10.0
35 48,xyyy 10.0
36 acute myeloid leukemia with recurrent genetic anomaly 10.0

Graphical network of the top 20 diseases related to Luminal Breast Carcinoma a:



Diseases related to Luminal Breast Carcinoma a

Symptoms & Phenotypes for Luminal Breast Carcinoma a

GenomeRNAi Phenotypes related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Salmonella-containing vacuole maturation GR00133-A-2 9.37 CAP1 ITGB5
2 Increased Salmonella enterica Typhimurium binding GR00133-A-3 9.32 CAP1 ITGB5
3 Increased Salmonella enterica Typhimurium effector injection GR00133-A-4 9.26 CAP1 ITGB5
4 Increased Salmonella enterica Typhimurium ruffling GR00133-A-5 9.16 CAP1 ITGB5
5 Increased Salmonella enterica Typhimurium membrane closure GR00133-A-6 8.96 CAP1 ITGB5
6 Decreased Tat-dependent HIV-LTR-beta-galactosidase protein expression GR00224-A-2 8.62 MED11 MED7

Drugs & Therapeutics for Luminal Breast Carcinoma a

Drugs for Luminal Breast Carcinoma a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Palbociclib Approved, Investigational Phase 3 571190-30-2 5330286
2
Goserelin Approved Phase 3 65807-02-5 5311128 47725
3 Protein Kinase Inhibitors Phase 3
4
Epirubicin Approved Phase 2 56420-45-2 41867
5
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
6
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
7
Tamoxifen Approved Phase 2 10540-29-1, 54965-24-1 2733526
8
Fulvestrant Approved, Investigational Phase 2 129453-61-8 17756771 104741
9
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
10
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
11
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
12
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
13
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
14 Anti-Bacterial Agents Phase 2
15 Alkylating Agents Phase 2
16 Antirheumatic Agents Phase 2
17 Antineoplastic Agents, Alkylating Phase 2
18 Antimitotic Agents Phase 2
19 Tubulin Modulators Phase 2
20 Antibiotics, Antitubercular Phase 2
21 Immunosuppressive Agents Phase 2
22 Immunologic Factors Phase 2
23 Estrogens Phase 2
24 Estrogen Receptor Antagonists Phase 2
25 Estrogen Antagonists Phase 2
26 Hormones Phase 2
27 Hormone Antagonists Phase 2
28 Antineoplastic Agents, Hormonal Phase 2
29 Estrogen Receptor Modulators Phase 2
30 Selective Estrogen Receptor Modulators Phase 2
31 Albumin-Bound Paclitaxel Phase 2
32 Aromatase Inhibitors Phase 2
33 Liposomal doxorubicin Phase 2
34
Carboplatin Approved 41575-94-4 10339178 38904
35
Levoleucovorin Approved, Experimental, Investigational 68538-85-2, 58-05-9, 73951-54-9 149436 6006
36
Irinotecan Approved, Investigational 97682-44-5, 100286-90-6 60838
37
Fluorouracil Approved 51-21-8 3385
38
Oxaliplatin Approved, Investigational 61825-94-3 43805 11947679 6857599

Interventional clinical trials:

(show all 11)
# Name Status NCT ID Phase Drugs
1 Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant® Completed NCT03447132 Phase 3 Fulvestrant 500mg;Palbociclib 125mg;Goserelin 3.6 MG;Placebos
2 Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women Completed NCT02400567 Phase 2 Fluorouracile;Epirubicin;Cyclophosphamide;Letrozole;Palbociclib
3 Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer Completed NCT01565499 Phase 2 Nab-paclitaxel
4 Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer Recruiting NCT04023292 Phase 2 Endocrine therapy
5 SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast): A Phase 2 Study on Fulvestrant Beyond Progression in Combination With Alpelisib for PIK3CA-mutated, Hormone-receptor Positive HER2 Negative Advanced Breast Cancer Recruiting NCT05392608 Phase 2 Alpelisib 150 MG Oral Tablet [Piqray];Fulvestrant
6 Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. Active, not recruiting NCT03283384 Phase 2 Letrozole;Chemotherapy;Ribociclib plus letrozole
7 Phi29 Motor Nanopore for Single Molecule Sensing: Breast Nipple Aspirate Fluid Recruiting NCT03715959
8 Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients Recruiting NCT05580887 mFOLFIRINOX;Doxorubicin;Cyclophosphamid;Paclitaxel;Carboplatin
9 Identification and Monitoring of Resistance to First-line Treatment With CDK 4/6 Inhibitors in Combination With Aromatase Inhibitors in Patients With Metastatic Luminal Breast Cancer Through Non-invasive Biomarkers Recruiting NCT04660435
10 Immediate Breast Reconstruction With Free Greater Omentum for Luminal Breast Cancer Patients Recruiting NCT03370250
11 A Clinical Translational Study on the Multi-gene Assays and RecurIndex for Predicting the Breast Cancer Recurrence Risk in Cross-strait Chinese Patients With Early-stage Luminal Breast Cancer Not yet recruiting NCT04972448

Search NIH Clinical Center for Luminal Breast Carcinoma a

Genetic Tests for Luminal Breast Carcinoma a

Anatomical Context for Luminal Breast Carcinoma a

Organs/tissues related to Luminal Breast Carcinoma a:

MalaCards : Breast, Bone Marrow, Lymph Node, Myeloid, T Cells, Brain, Smooth Muscle

Publications for Luminal Breast Carcinoma a

Articles related to Luminal Breast Carcinoma a:

(show top 50) (show all 651)
# Title Authors PMID Year
1
Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods. 62
35997652 2022
2
The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer. 62
36462463 2022
3
Clinicopathological Features of Breast Cancer in Relation to Exposure of Cycling Reproductive Hormones: A Multicenter Retrospective Study of 14,731 Patients Diagnosed with Invasive Breast Cancer. 62
36447408 2022
4
Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis. 62
36443319 2022
5
Functional Characterization of lncRNA152 as an Angiogenesis-Inhibiting Tumor Suppressor in Triple-Negative Breast Cancers. 62
35997635 2022
6
Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance. 62
35882754 2022
7
Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. 62
36341760 2022
8
A tumor-suppressive function for Notch3 in the parous mammary gland. 62
36205077 2022
9
Tinengotinib (TT-00420), a Novel Spectrum-Selective Small Molecule Kinase Inhibitor, Is Highly Active Against Triple Negative Breast Cancer. 62
36223547 2022
10
Beneficial effects of mifepristone treatment in breast cancer patients selected by the progesterone receptor isoform ratio: Results from the MIPRA trial. 62
36269797 2022
11
Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk. 62
35876925 2022
12
Classification of Subgroups with Immune Characteristics Based on DNA Methylation in Luminal Breast Cancer. 62
36361541 2022
13
A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer. 62
36041543 2022
14
ASO Visual Abstract: Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk. 62
35871670 2022
15
PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer. 62
36222718 2022
16
CHD4 mediates SOX2 transcription through TRPS1 in luminal breast cancer. 62
36075559 2022
17
Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells. 62
36077517 2022
18
FDG-PET/CT for Primary Staging and Detection of Recurrence of Breast Cancer. 62
35636977 2022
19
Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review. 62
35777273 2022
20
ASO Visual Abstract: Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer-Effects of Age and Tumor Ki67. 62
35776260 2022
21
Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. 62
35569077 2022
22
FGF7/FGFR2-JunB signalling counteracts the effect of progesterone in luminal breast cancer. 62
35726195 2022
23
Characterization of the Metabolome of Breast Tissues from Non-Hispanic Black and Non-Hispanic White Women Reveals Correlations between Microbial Dysbiosis and Enhanced Lipid Metabolism Pathways in Triple-Negative Breast Tumors. 62
36077608 2022
24
RUNX1 as a Novel Molecular Target for Breast Cancer. 62
35599145 2022
25
The Contribution of Imaging as a Prognostic Marker of Luminal Breast Cancer. 62
35536138 2022
26
Microcalcifications and Peritumoral Edema Predict Survival Outcome in Luminal Breast Cancer Treated with Neoadjuvant Chemotherapy. 62
35536129 2022
27
FOXF2 oppositely regulates stemness in luminal and basal-like breast cancer cells through the Wnt/beta-catenin pathway. 62
35660418 2022
28
A Regulatory Axis between Epithelial Splicing Regulatory Proteins and Estrogen Receptor α Modulates the Alternative Transcriptome of Luminal Breast Cancer. 62
35887187 2022
29
Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers. 62
35858357 2022
30
Accelerated Partial Breast Irradiation with Intraoperative Radiotherapy Is Effective in Luminal Breast Cancer Patients Aged 60 Years and Older. 62
35887613 2022
31
Ultrasensitive Detection of MCF-7 Cells with a Carbon Nanotube-Based Optoelectronic-Pulse Sensor Framework. 62
35694527 2022
32
Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082]. 62
35487836 2022
33
GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. 62
35676392 2022
34
Alpha-smooth muscle actin-positive cancer-associated fibroblasts secreting osteopontin promote growth of luminal breast cancer. 62
35690734 2022
35
Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment. 62
35717238 2022
36
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. 62
35337692 2022
37
Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer. 62
35581229 2022
38
Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis. 62
35181478 2022
39
Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1. 62
34935137 2022
40
Disentangling ERBB Signaling in Breast Cancer Subtypes-A Model-Based Analysis. 62
35625984 2022
41
Pretreatment Leukocyte Count Ratios as Metastatic Predictive Factors in Luminal Type Breast Cancer. 62
35633543 2022
42
[Multicenter real world study on the efficacy and safety of eribulin for the treatment of advanced breast cancer]. 62
35448926 2022
43
mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease. 62
34927257 2022
44
Epigenetic Factors as Etiological Agents, Diagnostic Markers, and Therapeutic Targets for Luminal Breast Cancer. 62
35453496 2022
45
Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer. 62
35296682 2022
46
Stratification of Prognosis by Biological Features Following Neoadjuvant Chemotherapy in Luminal Breast Cancer. 62
35241543 2022
47
Predicting the molecular subtype of breast cancer and identifying interpretable imaging features using machine learning algorithms. 62
34647174 2022
48
[GENOMIC PROFILING IN LUMINAL BREAST CANCER]. 62
35195972 2022
49
New Insights in the Interaction of FGF/FGFR and Steroid Receptor Signaling in Breast Cancer. 62
34977930 2022
50
Machine learning with multiparametric breast MRI for prediction of Ki-67 and histologic grade in early-stage luminal breast cancer. 62
34383145 2022

Variations for Luminal Breast Carcinoma a

Cosmic variations for Luminal Breast Carcinoma a:

8 (show top 50) (show all 5031)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM137960127 ZNF598 breast,NS,carcinoma,ER-PR-positive carcinoma c.610G>A p.E204K 16:2002326-2002326 9
2 COSM135195220 ZNF598 breast,NS,carcinoma,ER-PR-positive carcinoma c.610G>A p.E204K 16:2002326-2002326 9
3 COSM99169942 YWHAQ breast,NS,carcinoma,ER-PR-positive carcinoma c.536A>G p.Y179C 2:9588211-9588211 9
4 COSM86351284 YWHAQ breast,NS,carcinoma,ER-PR-positive carcinoma c.536A>G p.Y179C 2:9588211-9588211 9
5 COSM143036457 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.918G>A p.M306I 11:102206008-102206008 9
6 COSM126968360 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.384G>A p.M128I 11:102206008-102206008 9
7 COSM127993455 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.918G>A p.M306I 11:102206008-102206008 9
8 COSM85231921 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.918G>A p.M306I 11:102206008-102206008 9
9 COSM133267649 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.918G>A p.M306I 11:102206008-102206008 9
10 COSM90942881 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.804G>A p.M268I 11:102206008-102206008 9
11 COSM145023383 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.804G>A p.M268I 11:102206008-102206008 9
12 COSM128447016 YAP1 breast,NS,carcinoma,ER-positive carcinoma c.804G>A p.M268I 11:102206008-102206008 9
13 COSM105628484 XBP1 breast,NS,carcinoma,ER-positive carcinoma c.19G>A p.A7T 22:28800506-28800506 9
14 COSM85917792 XBP1 breast,NS,carcinoma,ER-positive carcinoma c.19G>A p.A7T 22:28800506-28800506 9
15 COSM142230116 XBP1 breast,NS,carcinoma,ER-positive carcinoma c.19G>A p.A7T 22:28800506-28800506 9
16 COSM89270241 XBP1 breast,NS,carcinoma,ER-positive carcinoma c.19G>A p.A7T 22:28800506-28800506 9
17 COSM85182140 WNT2 breast,NS,carcinoma,ER-PR-positive carcinoma c.321A>G p.E107= 7:117315338-117315338 9
18 COSM90882705 WNK1 breast,NS,carcinoma,ER-PR-positive carcinoma c.1490A>G p.K497R 12:859334-859334 9
19 COSM128158629 WNK1 breast,NS,carcinoma,ER-PR-positive carcinoma c.1490A>G p.K497R 12:859334-859334 9
20 COSM92018095 WNK1 breast,NS,carcinoma,ER-PR-positive carcinoma c.1490A>G p.K497R 12:859334-859334 9
21 COSM130230128 WNK1 breast,NS,carcinoma,ER-PR-positive carcinoma c.1490A>G p.K497R 12:859334-859334 9
22 COSM132341362 WNK1 breast,NS,carcinoma,ER-PR-positive carcinoma c.1490A>G p.K497R 12:859334-859334 9
23 COSM88293154 VHL breast,NS,carcinoma,ER-positive carcinoma c.413C>T p.P138L 3:10146586-10146586 9
24 COSM90651104 VHL breast,NS,carcinoma,ER-positive carcinoma c.341-3273G>A p.? 3:10146514-10146514 9
25 COSM90653783 VHL breast,NS,carcinoma,ER-positive carcinoma c.341-3201C>T p.? 3:10146586-10146586 9
26 COSM88290785 VHL breast,NS,carcinoma,ER-positive carcinoma c.341G>A p.G114D 3:10146514-10146514 9
27 COSM140071241 VAV1 breast,NS,carcinoma,ER-PR-positive carcinoma c.2103G>A p.K701= 19:6850739-6850739 9
28 COSM130163321 VAV1 breast,NS,carcinoma,ER-PR-positive carcinoma c.2031G>A p.K677= 19:6850739-6850739 9
29 COSM141193936 VAV1 breast,NS,carcinoma,ER-PR-positive carcinoma c.2034G>A p.K678= 19:6850739-6850739 9
30 COSM85972860 VAV1 breast,NS,carcinoma,ER-PR-positive carcinoma c.2133G>A p.K711= 19:6850739-6850739 9
31 COSM142340805 VAV1 breast,NS,carcinoma,ER-PR-positive carcinoma c.2199G>A p.K733= 19:6850739-6850739 9
32 COSM88837054 USP9X breast,NS,carcinoma,ER-PR-positive carcinoma c.3693A>T p.R1231S 23:41188000-41188000 9
33 COSM98536780 USP9X breast,NS,carcinoma,ER-PR-positive carcinoma c.3693A>T p.R1231S 23:41188000-41188000 9
34 COSM103478546 USP34 breast,NS,carcinoma,ER-PR-positive carcinoma c.4201C>A p.L1401I 2:61296853-61296853 9
35 COSM87092276 USP31 breast,NS,carcinoma,ER-PR-positive carcinoma c.721C>T p.H241Y 16:23108096-23108096 9
36 COSM93461611 USP16 breast,NS,carcinoma,ER-PR-positive carcinoma c.2344C>T p.P782S 21:29053952-29053952 9
37 COSM103742887 USP16 breast,NS,carcinoma,ER-PR-positive carcinoma c.2341C>T p.P781S 21:29053952-29053952 9
38 COSM103747829 USP16 breast,NS,carcinoma,ER-PR-positive carcinoma c.2344C>T p.P782S 21:29053952-29053952 9
39 COSM116184328 UQCC5 breast,NS,carcinoma,ER-positive carcinoma c.*114G>C p.? 3:52579160-52579160 9
40 COSM127063897 UBR5 breast,NS,carcinoma,ER-PR-positive carcinoma c.4392C>G p.F1464L 8:102293802-102293802 9
41 COSM127538052 UBR5 breast,NS,carcinoma,ER-PR-positive carcinoma c.4374C>G p.F1458L 8:102293802-102293802 9
42 COSM87429062 UBR5 breast,NS,carcinoma,ER-PR-positive carcinoma c.4392C>G p.F1464L 8:102293802-102293802 9
43 COSM144361724 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 9
44 COSM101929825 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1872C>T p.Y624= 15:25356787-25356787 9
45 COSM149764169 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1863C>T p.Y621= 15:25356787-25356787 9
46 COSM108914927 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 9
47 COSM107120943 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 9
48 COSM145837560 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 9
49 COSM135842312 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 9
50 COSM85309324 UBE3A breast,NS,carcinoma,ER-PR-positive carcinoma c.1803C>T p.Y601= 15:25356787-25356787 9

Expression for Luminal Breast Carcinoma a

Search GEO for disease gene expression data for Luminal Breast Carcinoma a.

Pathways for Luminal Breast Carcinoma a

Pathways related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.54 HJURP CENPA ASF1B
2
Show member pathways
11.2 HJURP H2BC14 CENPA

GO Terms for Luminal Breast Carcinoma a

Cellular components related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mediator complex GO:0016592 9.26 MED7 MED11
2 core mediator complex GO:0070847 8.92 MED7 MED11

Biological processes related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleosome assembly GO:0006334 9.63 H2BC14 CHAF1B ASF1B
2 CENP-A containing chromatin assembly GO:0034080 9.13 HJURP CENPA
3 DNA replication-dependent chromatin assembly GO:0006335 8.92 CHAF1B ASF1B

Molecular functions related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 histone binding GO:0042393 9.43 HJURP CHAF1B ASF1B
2 structural constituent of chromatin GO:0030527 9.02 H2BC14 CENPA ASF1B

Sources for Luminal Breast Carcinoma a

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....